BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15604894)

  • 1. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
    Marcucci G; Mrózek K; Bloomfield CD
    Curr Opin Hematol; 2005 Jan; 12(1):68-75. PubMed ID: 15604894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
    Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
    Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review.
    Baldus CD; Mrózek K; Marcucci G; Bloomfield CD
    Br J Haematol; 2007 Jun; 137(5):387-400. PubMed ID: 17488484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.
    Lin TL; Smith BD
    Am J Med Sci; 2011 May; 341(5):404-8. PubMed ID: 21522052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
    Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
    J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.
    Gaidzik V; Döhner K
    Semin Oncol; 2008 Aug; 35(4):346-55. PubMed ID: 18692685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances of study on prognostic factors of molecular biology in acute myeloid leukemia with normal cytogenetics].
    Han TJ; Xu XP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1063-8. PubMed ID: 20723330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia.
    Wakita S; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Koizumi M; Fujiwara Y; Yui S; Fukunaga K; Ryotokuji T; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Fukuda T; Inokuchi K
    Leukemia; 2016 Mar; 30(3):545-54. PubMed ID: 26488113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic abnormalities in acute myelogenous leukemia with normal cytogenetics.
    Wald D; Vermaat JM; Peleg G; Tse W
    Curr Hematol Malig Rep; 2008 Apr; 3(2):83-8. PubMed ID: 20425451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
    Schnittger S; Schoch C; Dugas M; Kern W; Staib P; Wuchter C; Löffler H; Sauerland CM; Serve H; Büchner T; Haferlach T; Hiddemann W
    Blood; 2002 Jul; 100(1):59-66. PubMed ID: 12070009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC.
    Hirsch P; Tang R; Marzac C; Perrot JY; Fava F; Bernard C; Jeziorowska D; Marie JP; Legrand O
    Haematologica; 2012 Feb; 97(2):241-5. PubMed ID: 22058196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
    Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics.
    Cagnetta A; Adamia S; Acharya C; Patrone F; Miglino M; Nencioni A; Gobbi M; Cea M
    Leuk Res; 2014 Jun; 38(6):649-59. PubMed ID: 24726781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.
    Gregory TK; Wald D; Chen Y; Vermaat JM; Xiong Y; Tse W
    J Hematol Oncol; 2009 Jun; 2():23. PubMed ID: 19490647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.
    Baldus CD; Thiede C; Soucek S; Bloomfield CD; Thiel E; Ehninger G
    J Clin Oncol; 2006 Feb; 24(5):790-7. PubMed ID: 16418499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.